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Abstract
Background Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disease, and accounts for a substantial 
proportion of unplanned hospital admissions. Care bundles for COPD are a set of standardised, evidence-based interventions 
that may improve outcomes in hospitalised COPD patients. We estimated the cost effectiveness of care bundles for acute 
exacerbations of COPD using routinely collected observational data.
Methods Data were collected from implementation (n = 7) and comparator (n = 7) acute hospitals located in England and 
Wales. We conducted a difference-in-difference cost-effectiveness analysis using a secondary care (i.e. hospital) perspective 
to examine the effect on National Health Service (NHS) costs and 90-day mortality of implementing care bundles compared 
with usual care for patients admitted to hospital with an acute exacerbation of COPD. Adjusted models included as covari-
ates patient age, sex, deprivation, ethnicity and seasonal effects and mixed effects for site.
Results Outcomes and baseline characteristics of up to 12,532 patients were analysed using both complete case and multiply 
imputed models. Implementation of bundles varied. COPD care bundles were associated with slightly lower secondary care 
costs, but there was no evidence that they improved outcomes once adjustments were made for site and baseline covariates. 
Care bundles were unlikely to be cost effective for the NHS with an estimated net monetary benefit per 90-day death avoided 
from an adjusted multiply imputed model of −£1231 (95% confidence interval − £2428 to − £35) at a high cost-effectiveness 
threshold of £50,000 per 90-day death avoided.
Conclusion and Recommendations Care bundles for COPD did not appear to be cost effective, although this finding may 
have been influenced by unmeasured variations in bundle implementation and other potential confounding factors.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-020-00207 -w) contains 
supplementary material, which is available to authorized users.
 * Padraig Dixon 
 Padraig.dixon@bristol.ac.uk
1 Population Health Sciences, Bristol Medical School, 
University of Bristol, Canynge Hall, 39 Whatley Road, 
Bristol BS8 2PS, UK
2 MRC Integrative Epidemiology Unit, University of Bristol, 
Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
3 Department of Health and Applied Sciences, University 
of the West of England, Bristol BS16 1DD, UK
4 North Bristol Trust, Southmead Hospital, Bristol BS10 5NB, 
UK
 P. Dixon et al.
Key Points for Decision Makers 
Care bundles for chronic obstructive pulmonary dis-
ease (COPD) are a set of standardised, evidence-based 
interventions that may improve outcomes in hospitalised 
COPD patients.
We estimated the cost effectiveness of care bundles for 
acute exacerbations of COPD using routinely collected 
observational data. We compared hospital costs with 
90-day mortality in 14 hospitals that implemented care 
bundle interventions to varying degrees.
COPD care bundles were associated with slightly lower 
secondary care costs, but there was no evidence that they 
improved mortality. There was no evidence that care 
bundles were likely to be cost effective for COPD.
1 Introduction
Chronic obstructive pulmonary disease (COPD) refers to 
set of long-term respiratory diseases that encompass several 
pathologies that affect the lungs and inhibit airflow, includ-
ing chronic bronchitis and emphysema. The prevalence of 
COPD in the United Kingdom (UK) is estimated to con-
stitute 1.2 million diagnosed cases [1], and up to 2 million 
undiagnosed cases [2]. The condition is associated with 
approximately 30,000 deaths annually [1] in the UK.
Managing COPD in secondary care requires substantial 
resources. In the UK, COPD is responsible for 12% of all 
ambulatory care sensitive hospital admissions [3]. Some 
23% of patients admitted for COPD will be re-admitted for 
COPD at least once within 90 days of discharge [4], and 
the condition is the single most common cause of readmis-
sion in the NHS [5]. The financial sustainability of publicly 
funded healthcare services, such as the National Health Ser-
vice (NHS) in the UK, depends in large part on the efficient 
management of chronic conditions—such as COPD—that 
are associated with substantial numbers of potentially avoid-
able admissions and readmissions.
Care bundles may improve patient outcomes and reduce 
the resources required to manage COPD. These bundles are 
sets of simple, structured, evidence-based clinical actions or 
interventions intended to improve patient outcomes [6] and 
are administered as part of inpatient hospital care. Admis-
sion care bundles and discharge care bundles for COPD were 
developed by the British Thoracic Society in conjunction 
with NHS Improvement [7].
The admission bundle, administered at hospital admis-
sion, is intended to facilitate coordinated care for admissions 
following an acute exacerbation of COPD. For example, an 
important first step in this bundle is correctly establishing 
a diagnosis of an acute exacerbation of COPD, supported 
by electrocardiogram and X-ray. The discharge bundle is 
primarily intended to reduce re-admissions by ensuring 
appropriate assessment prior to discharge and to ensure that 
patients are confident in their use of medications. For exam-
ple, patients should have respiratory medicines reviewed and 
inhaler technique assessed before leaving hospital [8].
Specimen examples of admission and discharge bundles 
are available here (admissions: https ://www.brit-thora cic.
org.uk/docum ent-libra ry/quali ty-impro vemen t/copd/copd-
admis sion-care-bundl e/disch arge: https ://www.brit-thora cic.
org.uk/docum ent-libra ry/quali ty-impro vemen t/copd/copd-
disch arge-care-bundl e/) from the British Thoracic Society. 
The elements of each of these bundles are as follows:
Admission bundle:
• Ensure correct diagnosis of an acute exacerbation of 
COPD
• Assess oxygen and prescribe target range
• Recognise and respond to respiratory acidosis
• Administer steroids and nebulisers within 4 h of admis-
sion
• Respiratory team review within 24 h
Discharge bundle:
• Review medication and demonstrate inhaler use
• Provide self-management plan and emergency drug pack
• Assess and offer referral for smoking cessation
• Assess suitability for pulmonary rehabilitation
• Arrange follow-up call within 72 h of discharge
Note that these are examples of what might constitute 
the elements of admission and discharge bundles, and local 
variations are possible and were observed during the study. 
However, in all cases, the individual elements of each care 
bundle are generally based on clinical evidence, but there 
is little to no evidence as to whether the use of COPD care 
bundles themselves in routine clinical settings might be cost 
effective. We therefore estimated the cost effectiveness of 
both admission and discharge care bundles using observa-
tional patient-level data from 14 hospital sites located in 
England and Wales. This cost-effectiveness study was part of 
a wider project evaluating the effectiveness of care bundles 
for acute exacerbations of COPD [8–10].
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2  Methods
Acute hospitals with an emergency department and provid-
ing adult respiratory in-patient care in England and Wales 
formed the target population for the study. Following expres-
sions of interest in participating in this study, 14 hospitals 
were allocated to either an ‘implementation’ group or a 
‘comparator’ group. Hospitals in the implementation group 
delivered both admission and discharge bundles. Compara-
tor hospitals were selected for the implementation hospitals 
based on a number of pre-specified criteria including the 
number of COPD admissions, 28-day re-admission rates and 
COPD mortality rates. This resulted in seven implementa-
tion and seven comparator sites. Data were analysed using a 
controlled before-and-after study design [8].
2.1  Data Collection
Data from all sites were requested. We aimed to collect 
24 months of data, encompassing the 12 months immedi-
ately preceding index date (the date of the introduction of 
COPD care bundles in the implementation group and the 
equivalent date in the comparator) and the 12-month period 
following their introduction. Index dates for the introduction 
of both admission and discharge bundles at implementation 
sites ranged between 2013 and 2015. Comparator sites were 
allocated index dates on a comparable basis to those of the 
implementation sites.
Sites provided pseudo-anonymised patient-level data 
including age, sex, ethnicity, ICD-10 diagnosis codes [11], 
admission data and 90-day mortality via linkage to death 
registry information for all patients admitted for an acute 
exacerbation of COPD (ICD-10 diagnostic codes J41–J44) 
during the study period. The use of elements of COPD 
care—such as non-invasive ventilation—was requested from 
the medical records of a random sample at each site of 140 
adult patients admitted for an acute exacerbation of COPD.
2.2  Cost Perspective for Economic Analysis
We adopted a secondary (hospital) health system (i.e. NHS) 
perspective for costs, which were expressed in 2015/16 
prices and were not discounted over the 12 months before 
and after the index date.
2.3  Measurement and Valuation of Resource Use
Sites provided patient-level data for individuals admitted to 
hospital (‘admitted patient care’) with a primary diagnosis 
of COPD during the study period. In addition to admitted 
patient care, we also collected data on critical care, emer-
gency care and outpatient care. We assumed that there was 
no systematic difference between patients attending com-
parator and implementation hospitals in the use of COPD-
related hospital care outside those included in our analysis.
Resource use was costed for each care type using the 
Healthcare Resource Groups (HRGs) produced by appli-
cation of Reference Cost Grouper software [12] for each 
financial year.1 See Appendix 2 in the electronic supplemen-
tary material for further detail on the data processing steps 
involved. HRGs reflect groups of similar activity undertaken 
(based on OPCS-4 [13] procedure codes) for similar diagno-
ses (based on ICD-10 diagnosis codes).
The Grouper software was used to convert information 
concerning patient procedures, diagnoses and other data into 
‘Finished Consultant Episode’ HRGs. HRGs were linked 
to unit costs reported in NHS Reference Costs [14]. Costs 
relating to critical care, emergency care and outpatient care 
were included only if they occurred on or after the date of 
the first included inpatient COPD-related admission. Diag-
nostic information pertaining to outpatient care is relatively 
limited, and for many patients, not all outpatient attendances 
after the index inpatient admission will relate to COPD. We 
therefore undertook a sensitivity analysis in which we calcu-
lated hospital costs excluding the costs of outpatient attend-
ance. Costs for longer-staying patients were reported as the 
sum of the Finished Consultant Episode cost and the sum of 
per diem excess bed day costs.
Data collected from the medical records on patient use of 
discrete elements of COPD care were used to compare the 
costs of these elements between implementation and com-
parator sites on an ‘available case’ or ‘complete case’ basis. 
This analysis was conducted separately from the main cost-
effectiveness analysis because the costs of many individual 
elements are likely included in the HRG costing analysis. 
Element-specific resource use was valued using NHS Ref-
erence Costs [14], the NHS drug tariff [15], Unit Costs of 
Health and Social Care [16] and/or from published literature. 
Further details are provided in Appendix 3 of the electronic 
supplementary material.
2.4  Outcome Measurement
The proportion of patients alive at 90 days following the 
index admission was used as the outcome for effectiveness 
in the economic analysis. The cost-effectiveness results may 
therefore be interpreted as the incremental cost per percent 
change in the proportion of patients surviving until at least 
day 90.
1 Some sites reported data in the 2016/17 financial year, which was 
valued in 2015/16 terms using the Grouper and Reference Cost data 
for that year.
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2.5  Accounting for the Observational Study Design
Allocation of sites to implement care bundles was not ran-
dom and estimates of cost effectiveness of COPD bundles 
were at risk of bias because patient costs and survival may 
systematically differ between implementation and com-
parator sites and over time for reasons unconnected to the 
administration of a care bundle. Moreover, there was some 
degree of prior implementation of care bundles in some of 
the comparator sites, although we did not have access to 
the precise timing and nature of this implementation. The 
attempt to have comparable sites in both groups provides a 
partial but incomplete means of reducing this bias.
To mitigate other risks of bias due to confounding, we 
attempted to follow wherever possible the checklist criteria 
of Kreif et al. [17] for observational cost-effectiveness analy-
ses. A summary version of the checklist and the methods 
used to comply with its recommendations is available in 
Appendix 1 of the electronic supplementary material. We 
examined whether there were baseline covariates that pre-
dicted the use of care bundles by plotting histograms for age 
at admission and quintiles of deprivation, and by calculating 
standardised differences [18] for sex and ethnicity.
The regression models estimated implicitly embody a 
‘parallel trends’ assumption in their analysis of the before 
and after data: that pre-bundle trends in costs and mortal-
ity were similar between each site type, and that compara-
tor sites were not affected by the introduction of bundles at 
implementation sites. Using the preferred final specification 
on complete case data, we also estimated a ‘placebo regres-
sion’ to test this assumption. We assumed care bundles were 
introduced at implementation sites half-way through the year 
before their actual introduction. If the parallel trend assump-
tions hold, then no significant effect on net benefit and on 
the interaction between time period and site type should be 
evident before care bundles were introduced, in the absence 
of chance and a systematic difference between the imple-
mentation and comparator sites.
2.6  Regression Analysis
Two types of regression model were estimated to account 
for the sensitivity of the cost-effectiveness conclusions to 
structural uncertainty associated with the choice of statisti-
cal method: seemingly unrelated regressions (SURs), and 
net benefit regression. We estimated univariate net benefit 
regression models [19], in which patient-level incremen-
tal net benefit was regressed on a treatment indicator and 
covariates according to specification. We estimated SURs in 
which cost and mortality data were separately modelled but 
with a correlated error structure. We also explored general-
ised linear models, but these models did not converge except 
for the simplest specifications and are not discussed further.
All regression models included an interaction between 
study period (before and after the introduction of care bun-
dles) and site type (implementation and comparator sites), in 
which the treatment effect of care bundles is the coefficient 
on the interaction between study period and site type. We 
attempted to estimate each type of regression under three 
specifications: unadjusted for any covariates other than the 
period/site interaction, adjusted for the month when bundles 
were introduced and a mixed effect for each hospital trust, 
and finally a fully adjusted model accounting for month of 
bundle introduction, mixed effect for hospital trust, and 
baseline covariates. These baseline covariates comprised age 
at admission, sex, ethnicity (coded as ‘white’ and ‘other’ due 
to low frequencies in non-white categories), and deprivation 
quintile based on the Index of Multiple Deprivation asso-
ciated with the postcode of the patient’s residence. Mixed 
effect terms are random effects intended to capture varia-
tion not explained by these other covariates. These models 
therefore comprise a mix between the ‘fixed’ effects such as 
age and sex and the random effects that reflect other sources 
of variation.
2.7  Reporting of Results
Cost-effectiveness results were expressed using net mon-
etary benefit (NMB) statistics, calculated as:
The Δ term is the incremental difference operator; Δcosts , 
for example, represents the cost difference between imple-
menter and comparator sites. The lambda ( ) term represents 
the cost-effectiveness threshold. This captures the rate at 
which the health system converts monetary resources into 
avoided 90-day mortality. Different threshold values (£5000, 
£10,000, £20,000, £30,000 and £50,000) were used in esti-
mating NMB in the absence of a specific 90-day survival 
cost-effectiveness threshold in the NHS. This information 
can be used by decision makers to assess whether the incre-
mental secondary care costs of care bundles and associated 
changes in the proportion of patients alive at 90 days might 
constitute a cost-effective use of health system resources.
Net benefit statistics, confidence intervals (CI) on net 
benefit statistics and cost-effectiveness acceptability curves 
(CEACs) were calculated parametrically from the SUR and 
net benefit regressions.
2.8  Missing Data
We implemented multiple imputation by chained equations 
in Stata 14 using the—ice—command [20, 21] to account 
for missing data, including for cost data that could not 
be assigned to an HRG code. The imputation model was 
stratified by site type and included all baseline variables, 
NMB = Δsurvival ∗  − Δcosts.
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cost data, site, site type, and the survival outcome. Pre-
dictive mean matching [20] was used to account for non-
Gaussian distributions. The number of imputed data sets 
(n = 40) created was chosen to be at least 100 times greater 
than the proportion of missing data [20]. The methods of 
Faria et al. [22] were used to reflect variation within and 
between the imputed datasets use in regression analysis. 
All analyses were conducted in Stata v14 (Statacorp: Col-
lege Station, TX, USA).
2.9  Qualitative Analysis
The quantitative cost-effectiveness analysis was comple-
mented by two additional pieces of information obtained 
from qualitative interviews and observations from a subset 
of study sites. First, the duration of interactions between 
clinical staff (doctors, nurses, health care assistants, 
and others) and COPD patients was observed on medi-
cal admissions units, acute wards and/or general wards. 
Patients were observed for up to 2 h to record the duration 
of any interactions between the patient and hospital staff. 
Second, a small sample of patients, selected purposively, 
were interviewed concerning their post-discharge engage-
ments with different healthcare resources. Further details 
are reported in Appendix 6 of the electronic supplemen-
tary material.
3  Results
Data from 12,532 patients undergoing emergency hospital 
admissions during the study period were analysed in the 
economic evaluation. The 14 sites providing these data were 
located across England and Wales and included district hos-
pitals and larger city hospitals.
3.1  Covariate Balance and Overlap
The results of covariate overlap and balance tests, described 
in more detail in Appendix 1 of the electronic supplementary 
material, were considered to be acceptable.
3.2  Missing Data
A total of 14 sites were recruited to provide individual level 
data. One site changed record systems 6 months into the 
study period and only provided 4 months of pre-index date 
data. Four sites provided data missing the last 1–2 months of 
90-day follow up. Two sites did not provide 90-day mortal-
ity outcomes for the last 90 days of follow-up. Regression 
models were estimated including a ‘month in year’ effect to 
account for the imbalances to which this gave rise.
Data on patient age and sex were complete. Ethnicity 
was missing for 2.9% of participants included in the analy-
sis sample, and deprivation data were missing for 1.6% of 
participants.
Nine of the 14 sites provided incomplete case note extrac-
tion data. Two sites from the same NHS Trust did not have 
capacity to complete two full sets of the case note extraction 
audit forms (i.e. 140 sets of notes each). As a compromise, 
they performed the case note extraction on 70 sets of notes at 
each of the two sites. This reduced the total number of case 
report forms (CRFs) that we received; seven other sites also 
failed to provide the full 140 case note extraction CRFs due 
to limited time and resources.
There were instances of missing cost data within each 
type of hospital care (Table 1). A total cost variable was 
created per individual by summing across these four cost 
categories, of which some 31.8% of data (34.2% comparator 
sites, 29.3% implementation sites) were coded as missing. 
Total cost data were more likely to be missing for compara-
tor sites than implementation sites (odds ratio 0.80, 95% CI 
0.74–0.86).
3.3  Cost and Mortality Data
Complete total cost data is summarised in Table 2, and for 
multiply imputed data in Table 3.
An important difference between the imputed and com-
pleted case data sources is that all 14 sites are represented 
in the imputed data. This is likely to be the biggest driver of 
differences in point estimates, which indicate higher mean 
levels of cost and relatively high differences between site 
types in the imputed compared with the complete case data. 
The proportion of patients alive at 90 days (Table 4) was 
slightly higher at implementation sites both before and after 






Admitted patient care 8.29 (1039) 2.07 (130) 14.53 (909)
Critical care 21.99 (2754) 30.78 (1932) 13.14 (822)
Emergency department 2.21 (277) 1.23 (77) 3.20 (200)
Outpatient 6.76 (847) 0.11 (7) 13.43 (840)
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the introduction of care bundles. Given negligible amounts 
of missing day in 90-day survival, imputed point estimates 
(and therefore point estimates of difference between site 
type) of these proportions were the same to two decimal 
places as the available case data in Table 4.
3.4  Performance of Different Estimators and Model 
Selection
Estimation difficulties due to model convergence issues 
and data sparsity limited model selection. Nevertheless, we 
explored Akaike Information Criterion (AIC) and Bayes-
ian Information Criterion (BIC) statistics for SUR and 
net benefit models estimated on complete cases. We also 
present residual plots from complete case adjusted net ben-
efit regression model in Appendix 5 of the electronic sup-
plementary material. Net benefit and SUR models produced 
broadly similar results; results from net benefit regressions 
are reported below and results from SUR models in the elec-
tronic supplementary material (see Appendix 4).
3.5  Results of Cost‑Effectiveness Analysis
The probability of cost effectiveness attenuated on inclusion 
of covariates (Table 5). These results are similar to those 
of the SUR models reported in the electronic supplemen-
tary material. Both the AIC and the BIC were slightly lower 
under the fully adjusted net benefit models (AIC 170,741; 
Table 2  Summary of complete cost data per patient
CI confidence interval, SD standard deviation
a Confidence intervals calculated from unadjusted linear regression
Comparator sites Implementation sites Difference (95% CI)a
Mean cost (SD) Mean cost (SD)




£315 (18 to 612)




£705 (283 to 1128)




−£57 (− 461 to 347)
Table 3  Summary of imputed cost per patient
CI confidence interval, SE standard error
a Standard errors rather than standard deviations are reported for multiply imputed data
b Confidence intervals calculated from unadjusted linear regression
Comparator sites mean cost 
(SE)a
N = 6276




Total cost per patient £6750 (130) £5356 (131) −£1395 (−1757 to −1034)
Total cost per patient in pre-bundle period £7398 (189) £6070 (185) −£1328 (−1848 to −809)
Total cost per patient in post-bundle period £6057 (172) £4472 (183) −£1584 (−2072 to −1097)
Table 4  Proportion of patients 
alive at 90 days (complete 
cases)
CI confidence interval, SD standard deviation






















Cost Effectiveness of COPD Care Bundles
BIC 170,909) than the fully adjusted SUR models (AIC 
169,899; BIC 170,261).
We also ran two placebo regressions that estimated SUR 
and net benefit models on fully adjusted complete case data. 
Interaction effects in each model between site type and time 
period included the null. Moreover, estimated ‘cost effec-
tiveness’ measured using net benefit was much smaller 
than in the base case (net benefit model at a threshold of 
£20,000 = £233 [95% CI − 845 to 1311] compared with 
£798 in the base case). Figure 1 summarises the associated 
CEACs of the complete case analysis.
Complete case estimates may be biased (because of the 
exclusion of entire sites but also the exclusion of individual 
patient records in some cases) and inefficient (by exclud-
ing responses from over 31% of all individuals included in 
the sample). Table 6 presents results from the unadjusted, 
Table 5  Net monetary benefit at alternative values of the cost-effectiveness threshold—complete case analysis using net benefit regression
CI confidence interval, ICER incremental cost-effectiveness ratio, NMB net monetary benefit, λ cost-effectiveness threshold value
a Note that for net benefit regression, the interaction measures net benefit, and is reported above for a threshold value of £20,000
b Threshold values represent cost per death avoided at 90 days
c Interactions measure the difference in outcomes (either cost or 90-day survival) between (outcomes at implementation sites minus outcomes at 
comparator sites in the ‘pre’ period) and (outcomes at implementation sites minus outcomes at comparator sites in the ‘after’ period)
Models 
estimated
Net benefit regression, unadjusted
N = 8553
Net benefit regression, adjusted for 
month in year and mixed effect for trust 
cluster
N = 8553
Net benefit regression, adjusted for month 
in year, mixed effect for trust cluster, and 





























£11,926 £11,242 £884 (117 to 
1650)
£11,826 £11,361 £764 (2 to 
1527)






£13,411 £13,611 £13,400 £13,599 £13,396 £13,684
Cost-effectiveness  statisticsc
 NMB at λ = £5000 (95% CI) £792 (190 to 
1395)
£699 (99 to 
1300)
£784 (167 to 
1402)
 Probability cost effective at λ = £5000 1.00 0.99 0.99
 NMB at λ = £10,000 (95% CI) £823 (186 to 
1460)
£721 (87 to 
1355)
£789 (137 to 
1441)
 Probability cost effective at λ = £10,000 0.99 0.99 0.99
 NMB at λ = £30,000 (95% CI) £945 (− 1 to 
1891)
£809 (− 133 
to 1751)
£808 (− 158 to 
1774)
 Probability cost effective at λ = £30,000 0.97 0.95 0.95
 NMB at λ = £50,000 (95% CI) £1,067 
(− 309 to 
2442)
£899 (− 473 
to 2271)
£829 (− 576 to 
2234)
 Probability cost effective at λ = £50,000 0.94 0.90 0.88
Fig. 1  Cost-effectiveness acceptability curves (CEACs) for complete 
case net benefit models
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partially adjusted and fully adjusted models estimated with 
net benefit regression on imputed data.
Imputed regressions (Table 6) exhibit a declining prob-
ability of cost effectiveness, with the degree of attenuation 
on adjustment much more pronounced than in the complete 
case analysis. The partially and fully adjusted imputed mod-
els result in CEACs that were practically indistinguishable 
from the horizontal axis and hence are not displayed.
Overall, results were sensitive to imputation and adjust-
ment for covariates. Assuming that the imputation model is 
less biased than complete case models, this suggests that, 
once all sites are included in the analysis and adjustment is 
made for available covariates, there is little probability of 
care bundles being cost effective at any cost-effectiveness 
threshold. A sensitivity analysis excluding outpatient costs 
from the fully adjusted, imputed analysis was undertaken. 
This slightly reduced the estimated probability of care 
bundles being cost effective but overall results were similar 
to the base-case analysis.
We also conducted a simple threshold analysis to iden-
tify whether there was any level of costs at which net ben-
efit would likely be positive for the fully adjusted imputed 
analysis. For a cost-effectiveness threshold of £20,000 per 
90-day death averted, a 90% reduction in cost increased the 
probability of care bundles being cost effective to 17%, and a 
99% reduction increased the probability to 29%. This makes 
clear that, given the mortality outcomes observed, there is no 
plausible reduction in costs that would make the intervention 
more likely to be cost effective than not.
3.6  Elements of Care Bundles
A comparison between site types in the costs of care bundle 
elements is reported in Table 7. The sum of costs reported is 
Table 6  Net monetary benefit at alternative values of the cost-effectiveness threshold–imputed cases using net benefit regression
a Threshold values represent cost per death avoided at 90 days
CI confidence interval, NMB net monetary benefit, λ = cost-effectiveness threshold value
Models 
estimated
Net benefit regression, unadjusted model
N = 12,532 imputed observations
Net benefit regression, adjusted for month 
in year, and trust site as a mixed effect
N = 12,532 imputed observations
Net benefit regression, adjusted for 
month in year, trust site as a covariate, 
and baseline variables



























£10,580 £12,270 £282 (− 524 
to 1088)
£9942 £12,380 −£1099 
(− 1902 to 
− 296)







£12,148 £14,119 £12,867 £14,206 £12,898 £14,168
Cost-effectiveness  statisticsa
NMB at λ = £5000 (95% CI) £263 (− 452 
to 977)
−£1019 





Probability cost effective at λ = £5000 0.76 0.00 0.00
NMB at λ = £10,000 (95% CI) £269 (− 464 
to 1002)
−£1046 





Probability cost effective at λ = £10,000 0.75 0.00 0.00
NMB at λ = £30,000 (95% CI) £294 (− 622 
to 1210)
−£1150 





Probability cost effective at λ = £30,000 0.74 0.01 0.01
NMB at λ = £50,000 (95% CI) £319 (− 884 
to 1523)
−£1249 





Probability cost effective at λ = £50,000 0.70 0.02 0.02
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on an element-by-element complete case base. Appendix 3 
in the electronic supplementary material provides further 
detail on the costs of different elements and the sources used 
to construct them.
More costs are attributable to the admission care bundle 
than to the discharge bundle. It is notable that comparator 
sites incurred many of the costs associated with providing 
elements of care bundles, although these costs are lower than 
at implementation sites. This is consistent with evidence [9] 
that comparator sites also engaged in many of the ‘bundle’ 
activities undertaken by implementation sites.
4  Discussion
4.1  Strengths and Limitations
To our knowledge, this is the first study to estimate the cost 
effectiveness of care bundles for acute exacerbations of 
COPD. A large sample of detailed patient-level data was 
analysed under an observational design, complemented by 
comparisons of the use and cost of different elements of care 
bundles, and by qualitative assessments (see Appendix 6 of 
the electronic supplementary material) of the volume of care 
before and after discharge. This amounts to a diverse range 
of sources and methodological perspectives and reflects an 
effort to engage with ‘real-world evidence’ in the form of 
existing data sources and contemporary clinical practice.
The study has a number of limitations, many of which 
stem from the use of data sources not collected for research 
purposes. A fundamental and unavoidable challenge was that 
care bundles were implemented to varying degrees, at vary-
ing times by hospitals with different local cultures, manage-
ment practices and patient compositions. The reliability of 
care bundle implementation was not fully observable to the 
research team, particularly given the retrospective design 
used, and the absence of evidence in favour of cost effective-
ness may reflect a lack of efficacy or a lack of implementa-
tion to a degree at which efficacy could be reliably judged 
in comparative inferential analysis.
This limitation also complicates the interpretation of the 
cost-effectiveness results. The comparison in this analysis 
is not between ‘care bundles implemented’ and ‘care bun-
dles not implemented’. Instead, claims concerning the cost 
effectiveness of care bundles should be interpreted as a com-
parison between greater (at implementation sites) and lesser 
(at comparator sites) degrees of implementation. The results 
do not identify the cost effectiveness of care bundles per se, 
but rather the cost effectiveness of a more rather than less 
comprehensive implementation.
A limited number of baseline covariates were available, 
and confounding of the relationship between care bundles 
and the outcomes studied cannot be discounted, despite 
efforts to adhere to best practice in observational cost-effec-
tiveness analysis. For example, we did not have access to 
individual-level data on smoking history, which is the most 
important risk factor for incident COPD. Moreover, despite 
our expectation that some missing data would be encoun-
tered given the observational research design, data availabil-
ity was less than expected, despite efforts from the research 
team and staff at participating sites to secure access to data.
Comparisons between the complete case and imputed 
analysis were therefore complicated by the absence of data 
from entire sites for the former analysis models. However, 
given the comprehensive availability of mortality data, and 
that little difference was observed between types of site in 
relation to mortality, the precise details of the imputation are 
unlikely to have affected our overall conclusions regarding 
the outcome.
The reliance on 90-day mortality as the measure of effec-
tiveness of this analysis cannot identify other outcomes that 
may be relevant to the cost effectiveness of care bundles. 
Quality-of-life data is not routinely collected in the clinical 
environments from which we drew our data. This has the 
important consequence that we could not calculated qual-
ity-adjusted life-years (QALYs), which are the preferred 
outcome measure for cost-effectiveness analysis [23] per-
formed in the jurisdictions we study. It is possible that data 
on QALYs might not have changed our overall conclusions, 
given the modest mortality difference observed, and given 
the finding from the systematic review of van der Schans 
et al. [24] that the cost effectiveness of interventions for 
COPD tends to be driven by exacerbations and mortality. 
Nevertheless, the lack of quality-of-life data is an important 
limitation on our analysis.
The ward observations and post-discharge interviews con-
cerning community resource use, described in Appendix 6 
of the electronic supplementary material, offered limited 




 Comparator sites £298.32 (175.95)
 Implementation sites £349.91 (166.34)
 All sites £325.45 (172.89)
Admission bundle elements only
 Comparator sites £279.22 (168.27)
 Implementation sites £312.90 (160.10)
 All sites £296.78 (164.87)
Discharge bundle elements only
 Comparator sites £19.60 (24.71)
 Implementation sites £37.01 (33.28)
 All sites £28.68 (30.74)
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evidence concerning the impact of care bundles on health-
care costs. Some planned models could not be estimated, 
either because of sparsity in models with many indicator 
variables, or because of convergence issues when estimating 
mixed effects models. Placebo models testing the sensitiv-
ity of results to the timing of care bundle introduction were 
null. This offers a degree of reassurance that an ‘effect’ of 
care bundles on cost effectiveness is not obvious if they are 
modelled as having been introduced 6 months before their 
actual introduction and is some evidence that the parallel 
trends assumption may be reasonable. However, the nature 
of placebo tests means that these results are necessarily sug-
gestive rather than definitive since the absence of an ‘effect’ 
in the placebo test does not mean that the primary estimation 
models are themselves necessarily well posed, nor that the 
absence of evidence is evidence of absence.
5  Conclusions
The economic analysis of patient records from up to 12,532 
individuals receiving care indicated that a wider use of 
COPD care bundles was associated with slightly lower 
secondary care costs, but there was no evidence that this 
improved outcomes. Interpretation of these quantitative 
results is complicated by incomplete control of potential 
confounding variables, and partial implementation of care 
bundles. Patient observation and patient interviews with a 
small sample of individuals did not reveal any gross differ-
ences in resource use between site types.
Overall, observational analysis of these various sources of 
evidence using different methodological tools did not iden-
tify strong evidence that an extensive implementation of care 
bundles is likely to be cost effective when compared with 
less extensive implementation for the NHS in this patient 
group.
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